KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Return on Equity (2016 - 2025)

NovoCure (NVCR) has disclosed Return on Equity for 11 consecutive years, with 0.4% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 7.0% to 0.4% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.4% through Dec 2025, up 7.0% year-over-year, with the annual reading at 0.39% for FY2025, 8.0% up from the prior year.
  • Return on Equity hit 0.4% in Q4 2025 for NovoCure, up from 0.51% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.03% in Q1 2021 to a low of 0.55% in Q4 2023.
  • Historically, Return on Equity has averaged 0.32% across 5 years, with a median of 0.41% in 2023.
  • Biggest five-year swings in Return on Equity: plummeted -34bps in 2023 and later grew 8bps in 2024.
  • Year by year, Return on Equity stood at 0.14% in 2021, then crashed by -47bps to 0.21% in 2022, then crashed by -162bps to 0.55% in 2023, then increased by 15bps to 0.47% in 2024, then rose by 15bps to 0.4% in 2025.
  • Business Quant data shows Return on Equity for NVCR at 0.4% in Q4 2025, 0.51% in Q3 2025, and 0.48% in Q2 2025.